September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Vitreous cytokine profile immediately following phacoemulsification with posterior chamber intraocular lens placement
Author Affiliations & Notes
  • Sushant Wagley
    Ophthalmology, Michigan State University, Flint, Michigan, United States
  • Gina Yu
    Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Gianna C Teague
    Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Kameran Lashkari
    Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Jorge G Arroyo
    Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Sushant Wagley, None; Gina Yu, None; Gianna Teague, None; Kameran Lashkari, None; Jorge Arroyo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5043. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sushant Wagley, Gina Yu, Gianna C Teague, Kameran Lashkari, Jorge G Arroyo; Vitreous cytokine profile immediately following phacoemulsification with posterior chamber intraocular lens placement. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5043.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To quantify the immediate intraoperative effects of phacoemulsification with posterior chamber intraocular lens implantation (PE/PCIOL) on vitreous cytokines levels.

Methods : Vitreous samples collected during surgery were retrospectively analyzed in three groups: 1) patients that received PE/PCIOL immediately followed by pars plana vitrectomy (PPV), 2) patients that had previously received PE/PCIOL (pseudophakic) who underwent PPV at a later date, 3) those who never had PE/PCIOL (phakic) but only received PPV. Vitreous inflammatory cytokine markers were quantified and compared (using T-test) between these groups

Results : There was no significant difference in vitreous inflammatory cytokine levels between patients that received combined PE/PCIOL with PPV (Group 1) vs. phakic patients that only received PPV (Group 3). Patients who were pseudophakic and later received PPV (Group 2) had elevated inflammatory cytokines compared to those that received combined PE/PCIOL with PPV (Group 1) and had significantly elevated levels compared to phakic patients that only received PPV (Groups 3). There was significant elevations in Angiopoetin 2, PAI-1, IL-8, and TGF-alpha in Group 2 compared to Group 3 as well as significant elevations in Angiopoetin 2, PAI-1, sFASL, and PECAM-1 in Group 2 compared to Group 1.

Conclusions : While there is an eventual rise in vitreous cytokines, there is no significant immediate elevation of inflammatory cytokines following PE/PCIOL. Precise timing and quantification of inflammatory cytokines needs further analysis to understand intraocular inflammatory response following PE/PCIOL.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×